FogPharma’s Post

"DeepMirror is making AI for drug discovery as accesible as browsing the web". Go have a listen if you'd like to learn more about the work we're doing in the larger context of the AI revolution!

Check out the Alldus #AIinAction #podcast to learn more about how Alltrna applies #AI and #machinelearning to unlock #tRNA biology and scale #geneticmedicines for #rarediseases. #StopCodonDisease

Latest episode of Data in Biotech is now live! 🎙️ This week, Ross Katz sat down with Michael Nally, CEO at Generate:Biomedicines - a pioneer in generative biology that is transforming the way medicines are developed. Over this fascinating conversation, Mike shared his thoughts on the AI-driven drug development landscape and how data is set to change the way every drug is made in the future. We covered: → The latest in drug development trends, from how the availability of data accelerates what is possible to breakthroughs in de novo generation that allow proteins to be developed with unprecedented specificity. → Mike's view on the current status of machine learning's role in biotech R&D and how this will evolve. → How Generate innovates at each phase of AI-driven drug development. → And the value of Chroma, an open-source diffusion model from Generate that allows scientists to push the boundaries of protein discovery. Check it out on Apple, Spotify or wherever you get your podcasts. Apple: https://lnkd.in/e8y_hNUJ Spotify: https://lnkd.in/e8-K6KFu #data #biotech #drugdevelopment

Our CEO Michael Nally is featured on CorrDyn’s latest Data in Biotech podcast with Ross Katz, where he discusses how we are transforming drug development using #GenerativeAI. As an example, Mike shares: "The phase 1 data for GB-0669 [a monoclonal antibody targeting the S2 stem helix in SARS-CoV-2] has shown a significant improvement in safety and efficacy, which paves the way for our next stages of development. Our approach leverages #GenerativeBiology to design proteins that precisely target the intended conditions, thus reducing potential side effects and increasing therapeutic effectiveness." Want to hear more? Mike also discusses Chroma, our generative model for protein design, our culture, and our values of being audaciously ambitious, intrinsically digital, and patient-first, among other exciting topics. Listen to the full episode below 👇 #TeamGenerate | #ProteinEngineering

#ICYMI 𝐄𝐢𝐠𝐡𝐭 𝐃𝐫𝐮𝐠𝐬 𝐚 𝐖𝐞𝐞𝐤, 𝐄𝐩𝐢𝐬𝐨𝐝𝐞 10 – 𝐌𝐚𝐜𝐡𝐢𝐧𝐞 𝐥𝐞𝐚𝐫𝐧𝐢𝐧𝐠 𝐚𝐧𝐝 𝐀𝐈 𝐟𝐨𝐫 𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥𝐢𝐬𝐞𝐝 𝐭𝐡𝐞𝐫𝐚𝐩𝐲: 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐭𝐡𝐞𝐧 In this episode, we are lucky to be joined by two experts from the field of pharmacokinetic and pharmacodynamic modelling, Michael Neely and Jean-Baptiste Woillard. We hear about: 💡 The differences between traditional population pharmacokinetics and machine learning approaches in predicting drug exposure and optimizing dosing regimens. 💡Some advantages of ML approaches, including in handling nonlinear patterns. 💡The challenge of interpretability of results and dose recommendations from machine learning methods compared to traditional pharmacokinetic methods. 💡Which clinical contexts we will soon see machine learning derived models applied to clinical care. 💡The future of modelling and machine learning in pharmacology, including ethical considerations and the concept of augmented intelligence. 🎧 Tune in on your favorite podcast platform: Apple Podcasts 🔗 https://lnkd.in/gJd94qDh Google Podcasts🔗 https://lnkd.in/d65F7e8J Spotify 🔗 https://lnkd.in/gDixSbXx

Tune in to Episode 2 of ACRO's Good Clinical Podcast, where Stephen Pyke and the FDA's Dr. Tala Fakhouri discuss the massive potential of AI in clinical research. 🎙   Learn more about the FDA's evidentiary standards for AI, the importance of methodological transparency in submissions and how AI stands to streamline the drug development process, helping to bring life-changing medicines to market more efficiently. 💡 Stephen also sheds light on where AI advancements will show up and what it means for patients. 👇 Watch below! Don’t miss this fascinating discussion. Access the full episode here: https://lnkd.in/gdMz_agR #ACRO #GoodClinicalPodcast #ArtificialIntelligence 

In this enlightening episode, the Artificial Intelligence podcast sat down with Samantha Dale Strasser, the co-founder and CSO of Pepper Bio, a pioneering company in the world of transomics drug discovery. Discover the vital role of phosphoproteomic data, the challenges and innovations in integrating multiple -omics layers, and how AI is set to revolutionize clinical trials and drug discovery! https://lnkd.in/gDZCs-UH

We've got a new episode of Data in Biotech to share! This week Ross is joined by Jonathan Eads, VP of Engineering at Genomenon, to discuss how his work supports the company’s mission to make genomic evidence actionable.   The pair covered a lot of ground in this episode, including: → How Genomenon’s software works to log genomics literature and index genetic variants, providing critical evidence-based guidance for those working across biotech, pharmaceutical, and medical disciplines.   → The issues with inconsistent genetic data, variant nomenclature and extracting genetic variants from unstructured text before explaining how human curators are essential to ensure output accuracy.   → The opportunities and limitations of using AI and NLP techniques for genetic variant analysis. → And how Genomenon’s platform is being used to accelerate variant interpretation, disease diagnosis, and precision medicine development. Listen to the full episode wherever you get your podcasts - links to Apple and Spotify in the comments. #biotechpodcast #datainbiotech

“Start over from scratch with a blank canvas and say, hey, let's focus on the solution; let’s focus on solving the problem first.” When we spoke to Pradeep Ravindra on CorrDyn's Data in Biotech podcast, compliance was a hot topic. In a manufacturing context, the internal conversation often focuses on making everything compliant from the outset. Pradeep explains that rather than trying to create innovation within a compliance framework, manufacturers should create a sandbox in the cloud where data can be used to prototype innovations that can be tested and refined. Once there is a promising solution, then focus on clearing the compliance hurdle. You can read more of Pradeep’s insight here. https://lnkd.in/eunTZCKP

As the world of legal operations quickly evolves, check out this episode of the #PearlsOnGlovesOff podcast as host Mary O'Carroll and Sheila Dusseau, Head of Legal Ops at Ferring Pharmaceuticals, debunk common misconceptions about the process, the impact of AI, deriving strategic value through continuous learning, and more! https://spoti.fi/47Hga7e